Trial Profile
Combined Immunotherapy and oral chemotherapy to prevent recurrence of hepatocellular carcinoma after hepatectomy: a prospective randomized open controlled study.
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 24 May 2012
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Thymalfasin (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 21 May 2012 Planned end date changed from 1 Jun 2011 to 31 Dec 2011 as reported by Chinese Clinical Trial Register record.
- 22 Nov 2011 Additional lead trial center identified as reported by Chinese Clinical Trial Register record.
- 17 Mar 2011 New trial record